Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

PSA reconsidered.

[No authors listed]

Med Lett Drugs Ther. 2012 Aug 6;54(1396):61. Review. No abstract available.

PMID:
22869289
2.

Prostate cancer: PSA update--no change yet.

Phillips R.

Nat Rev Urol. 2014 Sep;11(9):483. doi: 10.1038/nrurol.2014.210. Epub 2014 Aug 19. No abstract available.

PMID:
25134834
3.

Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.

Djavan B.

Eur Urol. 2010 Jun;57(6):928-9. doi: 10.1016/j.eururo.2010.03.002. Epub 2010 Mar 9. No abstract available.

PMID:
20304552
4.
5.

[Early detection of prostatic carcinoma: Is PSA screening suitable?].

Kaulen H.

Dtsch Med Wochenschr. 2003 May 2;128(18):977. German. No abstract available.

PMID:
12755136
6.

Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.

Ito K.

Int J Urol. 2009 Sep;16(9):711-12. No abstract available.

PMID:
19777638
7.

Patient information - what is a PSA test?

Brett T.

Aust Fam Physician. 2011 Jul;40(7):501.

8.

Screening for prostate cancer.

Ruffin MT.

J Fam Pract. 1999 Aug;48(8):581-2. No abstract available.

PMID:
10496634
9.

[Prostatic specific antigen in practice in 1997].

Salomon L, Colombel M, Patard JJ, Chopin D, Abbou CC.

Ann Urol (Paris). 1998;32(2):69-72. Review. French.

PMID:
9599634
10.

PSA screening for prostate cancer: the current controversy.

de Koning HJ, Schröder FH.

Ann Oncol. 1998 Dec;9(12):1293-6. Review. No abstract available.

11.

[PSA based screening for prostatic cancer].

Johansen TE.

Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2612-4. Norwegian. No abstract available.

12.

Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.

Loeb S, Carter HB.

Urol Oncol. 2009 Nov-Dec;27(6):583-4. doi: 10.1016/j.urolonc.2009.06.011. No abstract available.

PMID:
19879470
13.

Prostate cancer: PSA as an intermediate end point in clinical trials.

Attard G, de Bono JS.

Nat Rev Urol. 2009 Sep;6(9):473-5. doi: 10.1038/nrurol.2009.130. No abstract available.

PMID:
19727145
14.

The story of the European Randomized Study of Screening for Prostate Cancer.

Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, Hugosson J, Lodding P, Recker F, Kwiatkowski M, Kirkels WJ; ERSPC.

BJU Int. 2003 Dec;92 Suppl 2:1-13. Review. No abstract available.

15.

[Screening for prostate cancer--what does the evidence show?].

Borre M, Iversen P.

Ugeskr Laeger. 2007 May 14;169(20):1887-8. Review. Danish.

PMID:
17553362
16.

PSA bounce versus biochemical failure following prostate brachytherapy.

Zelefsky MJ.

Nat Clin Pract Urol. 2006 Nov;3(11):578-9. Review. No abstract available.

PMID:
17088921
17.

[An update on the role of PSA and it's meaning in a hormone refractory patient].

Pagliarulo A.

Tumori. 2007 Mar-Apr;93(2):suppl 7-15. Review. Italian. No abstract available.

PMID:
17557583
18.

Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.

Borofsky MS, Makarov DV.

Nat Rev Urol. 2011 Jul 12;8(8):413-4. doi: 10.1038/nrurol.2011.87. No abstract available.

PMID:
21750502
19.

[The PSA test does not hold for screening. Good--but not good enough].

Holmström B, Johansson M, Bratt O, Stattin P.

Lakartidningen. 2010 Feb 17-23;107(7):436, 438-9. Review. Swedish. No abstract available.

PMID:
20384076
20.

[Prostatic carcinoma screening: sense ur nonsense?].

Madersbacher S, Vutuc C.

Wien Klin Wochenschr. 2009;121(13-14):428-30. doi: 10.1007/s00508-009-1199-2. German. No abstract available.

PMID:
19657603
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk